As presented in Figure 1(b), LOXL2 was significantly increased in CHOL, ESCA, GBM, HNSC, KIRC, LIHC, and STAD, whereas it was decreased in PRAD, compared with normal tissues. Here, LOXL2 is linked to prostate adenocarcinoma.